There were 592 press releases posted in the last 24 hours and 152,567 in the last 365 days.

Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 10:35 a.m.

/EIN News/ -- A live audio webcast will be available within the Investors & Media section of Rubius’ website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on Twitter.

Media Contact: 
Dan Budwick
1AB, Inc.
+1 (973) 271-6085
dan@1abmedia.com

Investor Contact:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 229-6122
lori.melancon@rubiustx.com

Rubius_Logo.jpg

Distribution channels: Conferences & Trade Fairs, Technology


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.